Answers are grounded in this paper and cite their sources.
Osteosarcoma remains one of the most aggressive bone malignancies, with limited advances in effective therapies. Herein, we developed injectable, in situ gel-forming hydrogels based on gellan gum (GG, 0.75% and 1.25% w/v), naturally extracted melanin nanoparticles (MNPs, 0-500 μg/mL), and Doxorubicin (Dox, 20 μg/mL) for localized chemo-photothermal therapy. Therapeutic efficacy was assessed using a physiologically relevant 3D osteosarcoma model mimicking post-surgical bone defects, generated by encapsulating Saos-2 cells within collagen hydrogels. Cells fully colonized the constructs within 7 days, remaining viable, proliferative, and expressing osteoblastic markers (Runx-2 and ALP). GG concentration modulated hydrogel rheology, injectability, water uptake, and degradation. Upon near-infrared (NIR) irradiation, MNP-loaded hydrogels reached temperatures above 60 °C within 5 min, reducing tumor cell viability to 43% after 24 h. Dox release profiles depended on MNP incorporation: GG(Dox) exhibited a burst release (~30% within 1 h), whereas GG(Dox-MNPs) enabled sustained release (~20% over 48 h). After 7 days of treatment, GG(Dox) reduced tumor viability to 11%, while GG(Dox-MNPs) achieved 27%. Overall, these hydrogels demonstrate strong chemo- and photothermal antitumor efficacy in a 3D osteosarcoma model, offering a versatile platform adaptable through controlled NIR irradiation and drug delivery.
No takes yet. Share an insight, caveat, or question.
Caldas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: